Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 18/20 | 0.49 |
| ▸ | ARG2 | P78540 | 18/20 | 0.49 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10265542 | 0.90 | ARG1 (0.51) | ARG1ARG2 | |
| SCHEMBL894629 | 0.85 | ARG1 (0.70) | ARG1ARG2 | |
| SCHEMBL20683332 | 0.82 | ARG1 (0.69) | ARG1ARG2 | |
| SCHEMBL10265101 | 0.81 | ARG1 (0.70) | ARG1ARG2 | |
| SCHEMBL29690210 | 0.81 | ARG1 (0.70) | ARG1ARG2 | |
| SCHEMBL10266331 | 0.81 | ARG1 (0.70) | ARG1ARG2 | |
| SCHEMBL10265095 | 0.81 | ARG1 (0.47) | ARG1ARG2 | |
| SCHEMBL10265531 | 0.80 | ARG1 (0.52) | ARG1ARG2 | |
| SCHEMBL10264924 | 0.77 | ARG1 (0.57) | ARG1ARG2 | |
| SCHEMBL20683339 | 0.77 | ARG1 (0.72) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885FFAR3 1953/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885FFAR3 1953/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885FFAR3 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.